Mandate

Vinge advises Xspray Pharma in connection with a directed share issue

January 31, 2018

The board of directors of Xspray Pharma proposes a directed share issue to be resolved at an extraordinary general meeting, whereby the company will receive approximately SEK 88 million before transaction costs.


The issue proceeds will primarily be invested in the development of new drug candidates, based on Xspray Pharma’s HyNap-platform. The share issue will be fully subscribed in accordance with separate agreements with the selected investors. Shareholders representing approximately 67.2 percent of Xspray Pharma’s shares have undertaken to vote in favor of the share issue at an extraordinary general meeting.

Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. The company’s shares are admitted to trading on Nasdaq First North.

Vinge’s team consists of Dain Hård Nevonen, Sabina Börjesson, Nils Fredrik Dehlin and Ramin Baradaran.

Related

Vinge has advised Triton in connection with sale of shares in Ambea AB (publ)

In total, 8.4 million shares were placed at a price of SEK 43.50 per share, corresponding to a total value of approximately SEK 365 million.
November 29, 2023

Vinge represents Lassie AB in a capital raising of SEK 260 million

Vinge has advised the pet insurance broker Lassie AB in connection with a capital raising of SEK 260 million in order to continue the expansion of the business.
November 29, 2023

Vinge advises Expedition Growth Capital in connection with its investment in Factbird 

Expedition Growth Capital, together with the Export and Investment Fund of Denmark (EIFO), have completed its investment in the Danish tech company Factbird. Vinge acted for Expedition Growth Capital in connection with the investment.
November 27, 2023